Serum and Urine Ghrelin in Adult Epileptic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03926273|
Recruitment Status : Completed
First Posted : April 24, 2019
Last Update Posted : April 24, 2019
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||Serum and Urine Ghrelin in Adult Epileptic Patients|
|Actual Study Start Date :||June 1, 2018|
|Actual Primary Completion Date :||January 30, 2019|
|Actual Study Completion Date :||February 5, 2019|
Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
- Serum ghrelin in Adult Epileptic Patients [ Time Frame: 6 months ]evaluation of the effect of Serum ghrelin in adult epileptic patients and in their response to anti- epileptic drugs
- Urine ghrelin in Adult Epileptic Patients [ Time Frame: 6 months ]evaluation of the effect of Urine ghrelin in adult epileptic patients and in their response to anti- epileptic drugs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926273
|Zagazig, El Sharkia, Egypt, 002|
|Principal Investigator:||nageeb rania, PI||zagazig U|